Skip to main content
. Author manuscript; available in PMC: 2013 Nov 3.
Published in final edited form as: Behav Pharmacol. 2010 Dec;21(8):745–753. doi: 10.1097/FBP.0b013e32833fa7b3

Table 1.

Summary of Mean Values

Measure Placebo d-Amphetamine
(8 mg)
d-Amphetamine
(16 mg)
d-Amphetamine
(24 mg)
Progressive-ratio
Number of capsules earned 1.1 3.3 4.5 2.6
Addiction Research Center Inventory
A 1.9 2.5 2.9 3.7
BG 5.4 6.1 6.3 7.0
PCAG 3.5 2.8 2.5 2.5
Adjective-Rating Scale
Stimulant Scale 4.8 7.5 9.9 10.9
Drug-Effect Questionnaire
Any Effect 2.0 18.7 28.6 33.7
Active-Alert-Energetic 2.0 18.3 30.9 33.3
Good Effects 1.8 13.9 24.6 30.7
Like Drug 1.7 17.0 32.1 36.1
Willing to Pay For 1.7 11.4 24.9 26.5
Stimulated 1.8 14.1 22.0 26.2
Talkative-Friendly 1.9 7.2 26.9 25.6
Rush 1.7 7.2 9.5 17.5
Bad Effects 1.7 7.3 5.5 6.9
Irregular-Racing Heartbeat 1.7 3.6 8.0 8.8
Restless 1.7 10.0 12.2 13.1
Shaky-Jittery 1.5 4.3 7.8 11.4
Digit-Symbol-Substitution-Task
Number of Trials Correct 64.4 65.2 68.0 67.9
Cardiovascular Measures
Systolic Pressure 115.7 122.8 128.6 131.5
Diastolic Pressure 73.4 78.7 80.7 83.2

Mean values are not included for a particular measure if the repeated-measure ANOVA failed to reveal a significant effect of Dose. Bold and underlined values indicate significant difference (p ≤ .05) from placebo according to post-hoc tests. A = Amphetamine; BG = Benzedrine Group; PCAG = Pentobarbital, Chlorpromazine, Alcohol Group.